Abstract：
UNASSIGNED: This study analyzes the efficacy and safety of tofacitinib in pediatric patients presenting with treatment-resistant uveitis and scleritis.
UNASSIGNED: Retrospective Chart Review.
UNASSIGNED: Nine children diagnosed with uveitis and one with scleritis received oral tofacitinib treatment. The median age of these patients was 9 years, with bilateral involvement observed in nine of them. Juvenile idiopathic arthritis was the most identifiable cause of uveitis, with anterior uveitis (50%) being the most frequent subtype of inflammation among these children. The median duration of immunosuppressive treatment before switching to tofacitinib was 18 (16-49) months. Remission of uveitis was achieved in all but two children, who experienced recurrence - manifesting as anterior uveitis. The median duration of follow-up in these children after tofacitinib treatment was 277.5 (183-549) days. At the end of follow-up, topical steroids could be withdrawn in six children, and two children were on topical steroids once a day. None of the children developed any systemic side-effect during the follow-up period. The mean BCVA at presentation was 0.62 ± 0.55, which improved to a mean of 0.27 ± 0.325 at the final follow-up (p = 0.0014).
UNASSIGNED: Treatment of pediatric uveitis with tofacitinib can be a valuable second-line treatment option and useful alternative in low- and middle-income countries.
UNASSIGNED: Retrospective Chart Review.
UNASSIGNED: Nine children diagnosed with uveitis and one with scleritis received oral tofacitinib treatment. The median age of these patients was 9 years, with bilateral involvement observed in nine of them. Juvenile idiopathic arthritis was the most identifiable cause of uveitis, with anterior uveitis (50%) being the most frequent subtype of inflammation among these children. The median duration of immunosuppressive treatment before switching to tofacitinib was 18 (16-49) months. Remission of uveitis was achieved in all but two children, who experienced recurrence - manifesting as anterior uveitis. The median duration of follow-up in these children after tofacitinib treatment was 277.5 (183-549) days. At the end of follow-up, topical steroids could be withdrawn in six children, and two children were on topical steroids once a day. None of the children developed any systemic side-effect during the follow-up period. The mean BCVA at presentation was 0.62 ± 0.55, which improved to a mean of 0.27 ± 0.325 at the final follow-up (p = 0.0014).
UNASSIGNED: Treatment of pediatric uveitis with tofacitinib can be a valuable second-line treatment option and useful alternative in low- and middle-income countries.
摘要：
■本研究分析了托法替尼在患有难治性葡萄膜炎和巩膜炎的儿科患者中的疗效和安全性。
■回顾性图表回顾。
■9例诊断为葡萄膜炎的儿童和1例巩膜炎的儿童接受口服托法替尼治疗。这些患者的中位年龄为9岁，其中9例观察到双边参与。幼年特发性关节炎是葡萄膜炎最明显的原因，前葡萄膜炎（50％）是这些儿童中最常见的炎症亚型。在改用托法替尼之前，免疫抑制治疗的中位持续时间为18（16-49）个月。除两个孩子外，所有孩子都实现了葡萄膜炎的缓解，谁经历了复发-表现为前葡萄膜炎。托法替尼治疗后这些儿童的中位随访时间为277.5(183-549)天。在后续行动结束时，六个孩子可以停用局部类固醇，两个孩子每天服用一次局部类固醇。在随访期间，所有儿童均未出现任何全身性副作用。演示时的平均BCVA为0.62±0.55，最终随访时平均为0.27±0.325（p=0.0014）。
托法替尼治疗小儿葡萄膜炎可能是一种有价值的二线治疗选择，在低收入和中等收入国家也是有用的替代方案。
■回顾性图表回顾。
■9例诊断为葡萄膜炎的儿童和1例巩膜炎的儿童接受口服托法替尼治疗。这些患者的中位年龄为9岁，其中9例观察到双边参与。幼年特发性关节炎是葡萄膜炎最明显的原因，前葡萄膜炎（50％）是这些儿童中最常见的炎症亚型。在改用托法替尼之前，免疫抑制治疗的中位持续时间为18（16-49）个月。除两个孩子外，所有孩子都实现了葡萄膜炎的缓解，谁经历了复发-表现为前葡萄膜炎。托法替尼治疗后这些儿童的中位随访时间为277.5(183-549)天。在后续行动结束时，六个孩子可以停用局部类固醇，两个孩子每天服用一次局部类固醇。在随访期间，所有儿童均未出现任何全身性副作用。演示时的平均BCVA为0.62±0.55，最终随访时平均为0.27±0.325（p=0.0014）。
托法替尼治疗小儿葡萄膜炎可能是一种有价值的二线治疗选择，在低收入和中等收入国家也是有用的替代方案。
